symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CAPR,2.84,4.055651,228439,73206396,0,2.75-8.22,-0.005,"Capricor Therapeutics, Inc.",USD,0001133869,US14070B3096,14070B309,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.capricor.com,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",Dr. Linda  Marb√°n Ph.D.,Healthcare,US,74,310 358 3200,10865 Road to the Cure,San Diego,CA,92121,1.36857,5.60857,https://financialmodelingprep.com/image-stock/CAPR.png,2007-02-13,False,False,True,False,False
